Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Investigation of Digital Media Use in Patients Receiving Chemotherapy

NCT07501871 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-04-20
Last updated
2026-04-21

Condition(s) studied

CancerChemotherapy

Investigational drug(s) / intervention(s)

No Intervention (Observational Study)

No Intervention (Observational Study): This is an observational study with no assigned intervention. Data will be collected through surveys assessing digital media use and eHealth literacy.

Study summary

This study aims to examine digital media use and eHealth literacy among patients receiving chemotherapy. Digital media has become an important tool for accessing health information, communicating with healthcare providers, and supporting self-management.

This observational study will be conducted with adult patients receiving chemotherapy in an outpatient setting. Data will be collected using a sociodemographic information form and the eHealth Literacy Scale (eHEALS). The findings are expected to contribute to a better understanding of digital media use and digital health literacy levels in chemotherapy patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
67 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged between 18 and 67 years * Receiving chemotherapy treatment * Able to communicate and understand the study procedures * Voluntarily agree to participate in the study Exclusion Criteria: * Patients with cognitive impairment or communication difficulties * Patients who refuse to participate * Patients with incomplete questionnaire responses

Primary outcome measure(s)

  • Digital Media Use Level — At baseline (during chemotherapy treatment)
    Digital media use will be evaluated based on frequency, duration, and purpose of use through a structured questionnaire.

Trial sites (1)

FacilityCityRegionStatus
Acıbadem University Atakent Hospital Istanbul Küçükçekmece
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07501871 on ClinicalTrials.gov ↗ ← All trials in Turkey